The Future of Alzheimer’s: The Future of Everything interview with Dr Annelise Barron

Posted on October 30th, 2018

MaxWell’s director for science, Annelise Barron, was interviewed on The Future of Everything podcast. Click below to listen. It’s a fascinating conversation!

Stanford Professor Annelise Barron

Stanford Professor Annelise Barron

The battle against Alzheimer’s is reinvigorated
 
Alzheimer’s is a disease that has been well studied for over 100 years without a single effective treatment found. Fresh insights into Alzheimer’s are giving researchers renewed confidence that better treatments are just around the corner.​
 
Stanford Bioengineer, Dr Annelise Barron, says new science that was recently published and replicated indicates that viral and bacterial infections may be part of the what causes Alzheimer’s dementia – an infection and inflammation of the brain. 
 
Studies show that virtually all of Alzheimer’s Disease patient brains are playing host to a list of microbial infections, including:
– Herpes type 1 (mouth sores)
– Chlamydia pneumonia
– Syphilis spirochetes and others
 
Dr Barron and her team of researchers at Stanford and from all over the world discovered that LL-37 peptide – a “ninja protein” as she referred to it – preferentially binds amyloid beta, and fights off microbial infections of all kinds. Inducing LL-37 (also known as human cathelicidin antimicrobial peptide or CAMP) could be a way to prevent Alzheimer’s Disease, or perhaps treat it some day. LL-37 is triggered by vitamin D3 (sunshine), vitamin A (retinoids, found in vegetables) and exercise.
 
The host Russ Altman called the super peptide, “Long Life 37.” Interesting name. Let’s hope the name fits.
 
MaxWell Biosciences – a co-inventor – is now seeking partners to help commercialize ​the new compound which has been shown to induce the body’s own immune system to fight off infections, bind and detoxify Alzheimer’s associated plaques and assist in the healing of damaged tissues.